Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

62 results about "Estrogen-related receptor" patented technology

The ERRs are orphan nuclear receptors, meaning the identity of their endogenous ligand has yet to be unambiguously determined. They are named because of sequence homology with estrogen receptors, but do not appear to bind estrogens or other tested steroid hormones.

SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV

Use of estrogen related receptor-modulating aryl ethers

Therapeutic methods of using certain heterocyclic arylidene aryl ether compounds for treating diseases or disorders mediated through modulation of estrogen related receptor alpha are described.
Owner:JANSSEN PHARMA NV

Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators

The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV

Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use

Disclosed are compositions for treating an estrogen receptor (ER) or estrogen related receptor (ERR) mediated disorder, comprising a therapeutically effective amount of a compound selected from the group consisting of Compound Nos. 1-9, 7-2, 7-4, 7-5, 7-7, 7-8, 8-2 and 3-15 set forth herein or a pharmaceutically acceptable salt thereof, wherein said compound modulates estrogen receptors and / or estrogen-related receptors and methods for use of said compositions.
Owner:CITY OF HOPE

Compound used as estrogen-related receptor regulator and application of compound

The invention discloses a compound used as an estrogen-related receptor regulator and an application of the compound. The compound is a 1-hydrogen-1, 2, 3-triazole compound with a structure as shown in formula (I) as well as pharmaceutical acceptable salt or prodrug molecule. The compound as well as pharmaceutical acceptable salt or prodrug molecule can be used for preparing drugs for adjusting activity of estrogen relevant receptor (ERR), preventing and treating breast cancer (comprising diseases which are free of influence of an anti-estrogen method), prostatic cancer or metabolic diseases. The formula (I) is as shown in the specification.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI

Estrogen receptor-related receptor alpha (ERRalpha) and cartilage formation

InactiveUS20070054859A1Promote cartilage formationInhibit cartilage formationCompound screeningApoptosis detectionDiseaseMammal
Estrogen related receptor α (ERRα) is involved in control of cartilage formation in mammals. Increasing ERRα activity causes stimulation of cartilage formation, providing a means of therapeutic intervention in diseases such as arthritis which involve cartilage destruction. Compounds may be screened for their potential as therapeutics by screening their effect on ERRα cartilage promoting activity.
Owner:AUBIN JANE E +1

Reprogramming progenitor compositions and methods of use therefore

The invention generally features compositions comprising induced pluripotent stem cell progenitors (also termed reprogramming progenitor cells) and methods of isolating such cells. The invention also provides compositions comprising induced pluripotent stem cells (iPSCs) derived from such progenitor cells. Induced pluripotent stem cell progenitors generate iPSCs at high efficiency. In particular embodiments the invention is predicated upon increased expression of an estrogen related receptor and changes in the oxidative and glycolytic pathways.
Owner:RONALD M EVANS AGENT +1

SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS

ActiveUS20110294780A1BiocideOrganic chemistryAntiestrogen resistanceSacroiliitis
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV

Medical application of encoding gene ESRRA of estrogen-related receptor alpha (ERR alpha)

The invention relates to an application of an encoding gene ESRRA of an estrogen-related receptor alpha (ERR alpha) in preparation of a medicine for preventing or treating liver diseases. The liver diseases include non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), alcoholic fatty liver disease (AFLD), hepatic fibrosis, or cirrhosis. The adeno-associated virus is utilized to construct an ERRalpha overexpression vector system, and the fact that the ERR alpha gene and a delivery system of the ERR alpha gene can be used for preventing or treating the liver diseases is proved on various disease models.
Owner:CHINA PHARM UNIV

Macrobrachium rosenbergii estrogen-related receptor gene ERR and application thereof

The invention discloses a macrobrachium rosenbergii estrogen-related receptor gene ERR. The nucleotide sequence of the gene ERR is shown as SEQ ID NO:1, and the amino acid sequence of the gene ERR is shown as SEQ ID NO:2. The invention further discloses application of the recombined macrobrachium rosenbergii estrogen-related receptor gene ERR to environmental internal-secretion interfering-substance detection and pollution assessment, and macrobrachium rosenbergii ERR protein has important application value in the aspects of natural water environment internal-secretion interfering-substance (like NP) detection and pollution assessment.
Owner:海南永贺生物科技有限公司

Use of estrogen-related receptor alpha as diagnostic marker for glioma and related application

The present invention discloses use of estrogen-related receptor alpha (ERR alpha) as a diagnostic marker for glioma and related application, also discloses application of the ERR alpha and an activecomponent for down-regulating or blocking of expression of ERR alpha molecule in the glioma in preparation of a related kit and drug for diagnosis and treatment of the glioma, and provides a new method for diagnosis and treatment of the glioma.
Owner:复旦大学附属华山医院北院

Uses of estrogen correlated acceptor 2 in maintaining versatility of mouse embryo stem cell

The invention discloses a carrier construction method of a mouse Esrrb (estrogen-related receptor 2) gene and an application thereof in researches on mouse embryonic stem cells. Lack of the Esrrb in the mouse leads to stem cell differentiation of an epiblast and abnormal embryonic development, the embryo dies within ten and half a days during the development, which indicates that the Esrrb plays a very important role in maintaining normal embryonic development of the mammal. In the invention, the Esrrb is taken as a transcription factor which can maintain pluripotent function of the embryonic stem cells without depending on LIF (Leukemia Inhibitory Factor). The construction method of the recombinant of the invention and the application thereof in embryonic stem cells provide reference for studying how other transcription factors play a role in the embryonic stem cells.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI

Drug-resistant estrogen-related receptor gene LSERR of laodelphax striatellus, gene segment capable of reducing drug resistance of laodelphax striatellus and application of gene segment

The invention relates to a drug-resistant estrogen-related receptor gene LSERR of laodelphax striatellus, a gene segment capable of reducing drug resistance of laodelphax striatellus and an application of the gene segment. The sequence of the drug-resistant estrogen-related receptor gene LSERR of laodelphax striatellus is shown as SEQ ID NO.1. The sequence of the gene segment capable of reducing drug resistance of laodelphax striatellus is shown as SEQ ID NO.3. The gene segment is used for reducing drug resistance of laodelphax striatellus. The gene segment can be used for detecting drug resistance of laodelphax striatellus, and drug resistance management of laodelphax striatellus is realized.
Owner:JIANGSU ACAD OF AGRI SCI

Substituted thiophene compound as well as preparation method and application thereof

The invention relates to a thiophene compound and pharmaceutically acceptable salts thereof represented by a general formula I, a preparation method thereof, a pharmaceutical composition containing the thiophene compound or pharmaceutically acceptable salts thereof, and applications of the thiophene compound and the pharmaceutically acceptable salts. The thiophene compound and the pharmaceuticallyacceptable salts thereof are used as a novel estrogen-related receptor alpha (ERR[alpha]) inverse agonist. The compound can be used to treat diseases associated with ERR and ERR[alpha], such as cancer, osteoporosis, diabetes, aging resistance, weight loss, and the like. After further optimization and screening, the compound is expected to be developed into a novel medicine for preventing and treating tumors or other ERR[alpha] related diseases.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI

Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators

The present invention relates to compounds of formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV

A kind of 4-bromophenylurea compound that regulates the activity of estrogen-related receptors and its medical application

The invention discloses a novel 4-bromophenylurea compound with formula I for regulating estrogen-related receptor activity, a pharmaceutically acceptable salt thereof and applications thereof. The compound and its pharmaceutically acceptable salts can be used to prepare estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.
Owner:QILU UNIV OF TECH

A novel n-p-tolyl-benzamide compound that regulates the activity of estrogen-related receptors and its medical application

InactiveCN106543047BOrganic chemistryAmide active ingredientsESTROGENIC SUBSTANCESMedicine
The invention discloses a novel N-p-tolyl-benzamide compound with formula I for regulating the activity of estrogen-related receptors, a pharmaceutically acceptable salt thereof and applications thereof. The compound and its pharmaceutically acceptable salts can be used to prepare estrogen-related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRα) activity for the prevention and treatment of breast cancer, prostate cancer, gastric cancer, colon cancer Cancer, ovarian cancer, cervical cancer and other malignant tumors.
Owner:QILU UNIV OF TECH

Novel N-phenyl-benzamide-based estrogen-related receptor activity regulating compound and medical uses thereof

The present invention discloses a novel N-phenyl-benzamide-based estrogen-related receptor activity regulating compound having a structure represented by a formula I, a pharmaceutically acceptable salt and applications thereof, wherein the compound and the pharmaceutically acceptable salt thereof can be used for preparation of drugs for regulating the activity of estrogen-related receptors ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERRalpha) and preventing and treating breast cancer, prostate cancer, gastric cancer, colon cancer, ovarian cancer, cervical cancer and other malignant tumors. The formula I is defined in the specification.
Owner:QILU UNIV OF TECH

Novel 3-bromophenyl urea estrogen-related receptor activity regulation compound and medical use thereof

The invention discloses a novel 3-bromophenyl urea estrogen-related receptor activity regulation compound, its pharmaceutically acceptable salt and application thereof. The compound and its pharmaceutically acceptable salts can be used for preparation of drugs capable of regulating estrogen related receptor ERR-alpha (Estrogen-related receptor alpha, ERR-alpha or ERR alpha) activity, preventing and treating breast cancer, prostate cancer, gastric cancer, colon cancer, ovarian cancer, cervical cancer and other malignant tumors. (formula I).
Owner:QILU UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products